• UM Eye Research Centre (UMERC)
  • ra.umerc@um.edu.my
logo
logo

UMRG / INTERNAL GRANTS

BIL

PROJECT TITLE

SOURCES

RECIPIENTS

1

Physical Activity and Psychological status after Falls

UM

Nurliza Khaliddin

EXTERNAL

BIL

PROJECT TITLE

SOURCES

RECIPIENTS

1

Retinopathy of Prematurity Outcomes in Malaysia

University of Sydney

Chaw May May

2

The Role Of Pancreatic β Cell-specific Exosomal Micrornas In Pathogenesis Of Diabetic Macular Edema

Bayer Fund

Tengku Ain Fathlun Tengku Kamalden

3

Isolating And Characterizing Exosomal Micrornas In Tear Fluid In Diabetic Retinopathy

Alcon Research Institute

Tengku Ain Fathlun Tengku Kamalden

Nurliza Khaliddin

Nor Fadhilah Mohamad

CLINICAL RESEARCH (UNDER CLINICAL INVESTIGATION CENTRE, CIC)

BIL

PROJECT TITLE

SOURCES

RECIPIENTS

1

RGH MD25

A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating The Efficacy,

Safety, And Tolerability Of Cariprazine In A Dose-Reduction Paradigm In The Prevention Of Relapse In Bipolar I Disorder Patients Whose Current Episode Is Manic Or Depressive, With Or Without Mixed Features

Allergan Malaysia Sdn. Bhd.

Amir Samsudin (Co-Researcher)

2

RGH MD24

A Double-Blind, Placebo-Controlled, Randomized Withdrawal, Multicenter Clinical Trial Evaluating The Efficacy, Safety, And Tolerability Of Cariprazine In A Dose-Reduction Paradigm In The Prevention Of Relapse In Patients With Schizophrenia

Allergan Malaysia Sdn. Bhd.

Amir Samsudin (Co-Researcher)

3

MK-3475-B15

A phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15/EV 304)

Merck Sharp & Dohme (M Sdn Bhd)

Nor Fadhilah Mohamad

(Co-Researcher)

4

CDRB436J12301

A Randomized, double-blind, Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of Dafrafenib plus Trametinib in Previously Treated Patients with Locally Advanced or Metastatic, Radio-active Iodine Refractory BRAFV600E mutation-positive Differentiated Thyroid Cancer

Novartis Corporation (Malaysia) Sdn Bhd

Nor Fadhilah Mohamad

(Co-Researcher)

Last Update: 01/03/2022